Member Info for olderbutwiser

The Oxilio situation with NXP001 did appear to be a rather poor low-ball agreement both in terms of up-front payments and longer term payments - but presumably no-one else was showing interest and Nuformix was doing nothing with it - so on that basis it was better to let someone else move it along at their expense and hopefully reap some royalties in the nearer future rather than just sit on it. NXP001 was our least important product.
Now NXP002 and NXP004 are quite different situation and acknowledged to be our lead products.

The two large trades are a transfer (a sell from investment account and buy in ISA account).

I believe that AR and the BOD are quite cautious and measured. The Lanstead financing is currently looking like a very poor decision, unless of course, the bod are expecting some stonking good news relatively soon.
I think a deal for 004 could be on the cards relatively soon, and that the bod think so as well, which is why they agreed to the Lanstead financing – an 004 deal will give the necessary re-rating to the sp and could make the Lanstead deal look fantastic in retrospect.
Just my take on situation.

Mars1 - useful articles, thanks for posting.
Tend to agree with your last four posts.
Nxp004 could be as big or even bigger than nxp002.
Nxp004 presents many commercial options and different approaches that the BOD could take and the Merck aspect introduces even further options/ possibilities.
When one sees how much money these big pharma's throw around, it would be nice to see them throwing a big wad our way - surely they would be keen to buy nxp004 in order to provide an improved drug with less side-effects and to gain patent protection into 2040 and to avoid the possibility that another pharma (generic or other) buys nxp004 and starts selling the improved version, thereby severely reducing sales of their blockbuster drug in a few years time.
I too am hoping they are too busy rather than just tardy.
GLA

It’s a new week and so looked in hoping for some good news. Well perhaps tomorrow!
I notice that Soupdragon has not posted for well over a week now – most unusual for him – missing his informative posts – hope he is ok and just taking a holiday.

From beggar-all trades to 6,250,000 shares bought in the space of a few minutes!
Someone is keen.

Unlisted company shares seem to be largely based upon smoke and mirrors - they may have a declared value of 500k but not easy to sell and realise that money - unless the company eventually becomes listed.
Nice to see a couple of 1,000,000 buys today - hope that bodes well for the coming week.

Correction four Bed and ISA pairs of transactions today.
At 10.58, 12.02 (with two corrections), 14.21 and 16.14.
I mention it to show that they are not just simple sells - they are a matched sell and buy with both at very low trade prices.

And now looks like a third Bed and ISA pair of transactions going through through.
I ditched H&L a few years ago - found they offered very poor prices for all types of trades.

Looks like another bed and ISA just gone through.
People using their new tax year allowances to move shares into a zero tax and zero reporting account.

I understand your frustration FSX, the weeks do seem to drag by when one expects news and yet there is none.
Just being picky but we are more like a quarter through the month – but know what your sentiment was.
I have just looked back and it was the 02nd March that the DG appointment was announced. Now was it pure coincidence that on the 01st March 2022 Japan relaxed its travel restrictions to allow foreign/ UK business people to travel to Japan for pretty much the first time in two years and with minimal, if any, quarantine if vaccinated?
It was also on that RNS that AR said that "Furthermore, our search for a new CEO is progressing well and I look forward to announcing an appointment in due course." I assumed then that realistically it would be at least a month before we heard so I am now waiting for the news to drop.
I only look in every now and then, unless there is a RNS notification – find it reduces the frustration.
GLA

For AR (who I think is a relatively cautious person) to agree to the Lanstead deal he must be pretty confident of the news coming through and the potential for NXP002 and NXP004.
Since the sp was around the 1.35p mark when the deal was announced – then the BOD must have assumed that the sp would be well below the 2.0p break-even (to achieve the £1.65m to Nuformix) for the early months of the deal.
Now, the premise of the deal structure with Lanstead was that the BOD believe that the actual proceeds they will get will be more than £1.65m - and they were ‘betting’ that the news over the coming period will achieve that.
That means that the BOD were/ are confident that the sp will be at least 2.5p/ 3p in a number of months in order to achieve the average of 2.0p or greater.
Here’s hoping.

Last couple of trades are a matched investment account to isa account transfer. (The buy, shown first, of slightly less shares than the sell and the sell always right on the formal bid)
Similar linked trades were completed yesterday and the day before.

From the Oxilio news release:
‘LSHS is a specialist life science consultancy firm established by Dr Dan Gooding, comprising intellectual property assets relevant to Oxilio’s OXL001 programme.’ (Nuformix NXP001 programme)
So it appears that LSHS was specifically set up as consultancy related only to NXP001. Dan has now sold LSHS with all its NXP001 IP and related work and will provide support on NXP001 to Oxilio as required.
Totally separately Dan has been taken on by Nuformix as a consultant on NXP002 to specifically try to re-kindle interest from the 2019 previously interested company (Kissei? Or whoever).
I read it that Dan as well as being a director of TRx is operating as an independent consultant with two separate customers. A fairly standard arrangement. I do not see that Dan is owned or controlled by Oxilio or taking orders from them with regard to anything other than NXP001.
Just may take on it – having worked as a consultant in similar scenario myself.

From the Oxilio news release:‘LSHS is a specialist life science consultancy firm established by Dr Dan Gooding, comprising intellectual property assets relevant to Oxilio’s OXL001 programme.’ (Nuformix NXP001 programme)So it appears that LSHS was specifically set up as consultancy related only to NXP001. Dan has now sold LSHS to Oxilio with all its NXP001 IP and related work and will provide support on NXP001 to Oxilio as required.Totally separately Dan has been taken on by Nuformix as a consultant on NXP002 to specifically try to re-kindle interest from the 2019 previously interested company (Kissei? Or whoever) and potentially other work. I read it that Dan as well as being a director of TRx is operating as an independent consultant with two separate customers. A fairly standard arrangement. I do not see that Dan is owned or controlled by Oxilio or taking orders from them with regard to anything other than NXP001.Just my take on it – having previously worked as a consultant and in similar scenario myself albeit in different industry.

DG seems to have set himself up as a consultant leveraging his involvement and knowledge of NXP001 for Oxilio and now doing the same with his unique and specific involvement with NXP002 for Nuformix too. Could it really just be that simple?
As well as being paid good money to work as a consultant for Nuformix DG should also be motivated by his substantial owned shares and options in Nuformix.

Yes NXP004 is oncology, BUT the work has already been done to get it to a point where it can be licensed.
o Nuformix filed one patent application in September 2020 on new forms of this drug and has utilised certain of the proceeds from the March 2021 placing to do further research on novel forms
o This research was successful, identifying a new family of co-crystal forms, and in November 2021 the Company filed a second patent application, complementing the previous patent application on NXP004 co-crystals
o If the patent applications on these new forms are granted, there is potential for patent expiry to extend to 2040/2041
o We will seek to license NXP004 to the originator of the marketed drug to potentially extend their patent protection, potentially adding significant value for the originator.
Nuformix should now be talking to AZ and possibly generic companies and I cannot see any valid reason for involving Oxilio with NXP004 – it is ready for licensing as is and for Nuformix to reap any benefits.

DG’s involvement with Oxilio is really interesting.
Oxilio state they are ' a pioneering pharmaceutical drug development company working to identify, repurpose and commercialise existing drugs to address unmet needs in cancer therapy’ – So on that basis NXP002 and IPF would be a rather huge move away from their stated core business for a recently formed business..

Last couple of trades are a matched investment to isa account transfer. (The buy, shown first, of slightly less shares than the sell)
Similar matched trades were completed yesterday early afternoon.
Just for info.

Just catching up with recent posts.
Belated congrats Soupdragon for correctly 'guessing' Lynparza - perhaps the bod will soon feel able to tell the world a bit more about it! They are expending additional time and money to tie up additional patent aspects on NXP004 - so they must feel it is worthwhile effort.
By the way, drug solubility has a much greater importance and many more associated aspects than has been mentioned by our 'newcomer'.

"poorly water soluble drugs show a number of negative clinical effects including potentially serious issues of inter patient variability, higher costs, inefficient treatment and more importantly, increased risks of toxicity or even death."

https://www.ispe.gr.jp/ISPE/02_katsudou/pdf/201304_en.pdfcent events

We are well overdue some good news and a big jump in the sp - hopefully it is just around the corner.
GLA